Protective effect of cardamonin against acetic acid-induced ulcerative colitis in rats

Area of Science:

• Pharmacology
• Gastroenterology
• Natural Product Chemistry

Background:

• Ulcerative colitis (UC) is a debilitating inflammatory bowel disease.
• Cardamonin, a chalcone derivative, possesses known anti-inflammatory properties.
• The therapeutic potential of cardamonin for UC requires investigation.

Purpose of the Study:

• To evaluate the protective effects of cardamonin against acetic acid-induced colitis in a rat model.
• To investigate the underlying mechanisms of cardamonin's action, including its impact on inflammation, oxidative stress, and apoptosis.

Main Methods:

• Rats were administered cardamonin (10 or 30 mg/kg/day) orally for 14 days prior to colitis induction.
• Ulcerative colitis was induced via intrarectal instillation of acetic acid.
• Macroscopic, histopathological, and biochemical analyses (MDA, MPO, iNOS, NF-κB, TNFα, caspase-3, COX-2) were performed.

Main Results:

• Cardamonin treatment significantly reduced disease activity and macroscopic damage.
• Histopathological examination revealed reduced colonic deterioration in cardamonin-treated groups.
• Cardamonin suppressed key inflammatory markers (MPO, iNOS, NF-κB, TNFα), oxidative stress (MDA), and apoptosis-related proteins (caspase-3, COX-2).

Conclusions:

• Cardamonin exhibits a significant protective effect against acetic acid-induced colitis in rats.
• The therapeutic benefits are attributed to the compound's ability to mitigate inflammation, oxidative stress, and apoptosis.
• Cardamonin shows promise as a potential therapeutic agent for ulcerative colitis.